Therefore, we believe that the biological behavior and prognosis of ER(-)/PR(+) and ER(-)/PR(-) are different, and ER(-)/PR(+) is a distinct molecular subtype of breast cancer from ER(-)/PR(-). This evidence concerns the gene ESR1 and breast carcinoma.